Loading stock data…
Eli Lilly and Company (LLY)
$1184.01+21.00 (+1.81%)
Market OpenUpdated 3:21 PM EDT
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eli Lilly and Company in the Healthcare sector is trading at $1,196.03 with a market capitalization of $979.6B. Wall Street consensus targets $1,270.37 (27 analysts), implying a +6.2% move over the next 12 months. The stock is currently near its 52-week high of $1,249.45, remaining 18.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.80B↑ | $19.29B↑ | $17.60B↑ | $15.56B↑ | $12.73B |
| Gross Profit | $16.22B↑ | $15.92B↑ | $14.59B↑ | $13.11B↑ | $10.50B |
| Operating Income | $9.78B↑ | $8.99B↑ | $8.39B↑ | $7.02B↑ | $5.30B |
| Net Income | $7.40B↑ | $6.64B↑ | $5.58B↓ | $5.66B↑ | $2.76B |
Peer Comparison
JNJUNHPFE
Fundamentals
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$979.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
39.07
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.55%
ROE
Elite ROE. Management converts capital into profit efficiently.
81.02%
Volume
Today's trading volume
1.15M
Recent News
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
Gene-editing biotech debuts at $25, backed by Sanofi and Eli Lilly, with a roughly $440.3 million valuation.
Eli Lilly and Novo Nordisk Are Locked in a Legal War. Don’t Lose Sight of the Main Event.
The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.
This Catalyst Makes Eli Lilly a Top Growth Stock in 2026
Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the stock has barely moved. Here is whether that disconnect signals a buying opportunity or a trap.
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?
Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs.